Our study is the first demonstration that LC exhibits anti-tumor activity in lymphoma by targeting palmitoylation and fatty acid synthesis, suggesting that ZDHHC21/FASN axis can potentially be a promising therapeutic target for patients with DLBCL. The gene discussed is FASN; the disease is diffuse large B-cell lymphoma.